Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free STAA Stock Alerts

STAAR Surgical (STAA) Financials

STAAR Surgical logo
$26.18 +0.85 (+3.36%)
Closing price 04:00 PM Eastern
Extended Trading
$25.88 -0.30 (-1.15%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for STAAR Surgical

Annual Income Statements for STAAR Surgical

This table shows STAAR Surgical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/1/2016 12/30/2016 12/29/2017 12/28/2018 1/3/2020 1/1/2021 12/31/2021 12/30/2022 12/29/2023 12/27/2024 1/2/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.53 -12 -2.14 4.97 14 5.91 28 40 21 -20 -80
Consolidated Net Income / (Loss)		 -6.53 -12 -2.14 4.97 14 5.91 28 40 21 -20 -80
Net Income / (Loss) Continuing Operations		 -6.53 -12 -2.14 4.97 14 5.91 28 40 21 -20 -80
Total Pre-Tax Income 		-5.61 -12 -2.30 6.64 13 8.27 31 46 34 -9.05 -82
Total Operating Income		 -5.34 -13 -3.63 6.60 12 6.77 33 44 28 -13 -92
Total Gross Profit		 53 58 64 92 112 118 179 223 253 240 182
Total Revenue		 77 82 91 124 150 163 230 284 322 314 239
Operating Revenue		 77 82 91 124 150 163 230 284 322 314 239
Total Cost of Revenue		 24 24 26 32 38 45 52 61 70 74 57
Operating Cost of Revenue		 24 24 26 32 38 45 52 61 70 74 57
Total Operating Expenses		 58 71 68 85 100 112 145 180 225 252 274
Selling, General & Admin Expense		 20 22 19 24 29 34 44 55 72 90 86
Marketing Expense		 24 29 28 39 45 46 67 89 112 117 103
Research & Development Expense		 15 21 20 22 25 32 34 36 40 45 40
Other Operating Expenses / (Income)		 - - - - - - - - 0.00 0.00 17
Restructuring Charge		 - - - - - - - - 0.00 0.00 29
Total Other Income / (Expense), net		 -0.27 0.21 1.34 0.04 1.17 1.50 -2.04 1.75 5.60 3.56 9.45
Interest & Investment Income		 0.74 0.51 0.47 0.80 1.54 0.68 0.98 3.25 7.06 6.42 4.59
Other Income / (Expense), net		 -0.93 -0.30 0.87 -0.75 -0.37 0.82 -3.01 -1.50 -1.46 -2.86 4.86
Income Tax Expense		 0.93 -0.32 -0.16 1.67 -1.02 2.35 3.79 5.89 12 11 -1.82
Basic Earnings per Share		 ($0.17) ($0.30) ($0.05) $0.12 $0.32 $0.13 $0.58 $0.83 $0.44 ($0.41) ($1.62)
Weighted Average Basic Shares Outstanding		 39.26M 40.33M 41.00M 42.59M 44.49M 45.61M 47.21M 47.99M 48.52M 49.13M 49.57M
Diluted Earnings per Share		 ($0.17) ($0.30) ($0.05) $0.11 $0.30 $0.12 $0.56 $0.80 $0.43 ($0.41) ($1.62)
Weighted Average Diluted Shares Outstanding		 39.26M 40.33M 41.00M 45.26M 46.90M 47.95M 49.46M 49.38M 49.43M 49.13M 49.57M
Weighted Average Basic & Diluted Shares Outstanding		 39.26M 40.33M 42.80M 41.40M 44.96M 46.56M 47.75M 48.24M 48.87M 49.33M 49.51M

Quarterly Income Statements for STAAR Surgical

This table shows STAAR Surgical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/29/2023 3/29/2024 6/28/2024 9/27/2024 12/27/2024 3/28/2025 6/27/2025 9/26/2025 1/2/2026 4/3/2026 7/3/2026
Net Income / (Loss) Attributable to Common Shareholders		 7.76 -3.34 7.38 9.98 -34 -54 -17 8.88 -18 5.21 8.06
Consolidated Net Income / (Loss)		 7.76 -3.34 7.38 9.98 -34 -54 -17 8.88 -18 5.21 8.06
Net Income / (Loss) Continuing Operations		 7.76 -3.34 7.38 9.98 -34 -54 -17 8.88 -18 5.21 8.06
Total Pre-Tax Income 		14 -2.21 10 13 -30 -54 -26 19 -21 8.22 11
Total Operating Income		 10 -2.28 12 5.68 -28 -57 -30 18 -23 7.98 10
Total Gross Profit		 61 61 78 68 32 28 33 78 44 69 70
Total Revenue		 76 77 99 89 49 43 44 95 58 94 94
Operating Revenue		 76 77 99 89 49 43 44 95 58 94 94
Total Cost of Revenue		 16 16 21 20 17 15 12 17 14 25 24
Operating Cost of Revenue		 16 16 21 20 17 15 12 17 14 25 24
Total Operating Expenses		 50 63 67 63 60 85 63 59 67 61 60
Selling, General & Admin Expense		 17 23 24 22 21 24 21 21 20 17 23
Marketing Expense		 23 27 31 29 26 27 26 23 28 25 27
Research & Development Expense		 11 13 12 12 12 11 10 9.21 6.92 9.93 9.94
Restructuring Charge		 - 0.00 0.00 0.00 - 23 5.25 0.03 0.69 2.68 0.00
Total Other Income / (Expense), net		 3.33 0.07 -1.56 7.48 -2.42 2.92 4.05 0.30 2.19 0.24 0.92
Interest & Investment Income		 1.70 2.04 1.42 1.41 1.55 1.37 1.37 0.79 1.07 0.91 0.94
Other Income / (Expense), net		 1.64 -1.97 -2.99 6.07 -3.98 1.55 2.68 -0.49 1.11 -0.67 -0.02
Income Tax Expense		 5.98 1.13 2.96 3.18 3.89 -0.28 -9.10 9.91 -2.34 3.01 2.97
Basic Earnings per Share		 $0.15 ($0.07) $0.15 $0.20 ($0.69) ($1.10) ($0.34) $0.18 ($0.36) $0.10 $0.16
Weighted Average Basic Shares Outstanding		 48.52M 48.91M 49.13M 49.20M 49.13M 49.34M 49.52M 49.63M 49.57M 49.91M 50.32M
Diluted Earnings per Share		 $0.16 ($0.07) $0.15 $0.20 ($0.69) ($1.10) ($0.34) $0.18 ($0.36) $0.10 $0.16
Weighted Average Diluted Shares Outstanding		 49.43M 48.91M 49.81M 49.73M 49.13M 49.34M 49.52M 50.55M 49.57M 50.90M 51.50M
Weighted Average Basic & Diluted Shares Outstanding		 48.87M 49.13M 49.19M 49.28M 49.33M 49.53M 49.55M 49.74M 49.51M - 50.14M

Annual Cash Flow Statements for STAAR Surgical

This table details how cash moves in and out of STAAR Surgical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/1/2016 12/30/2016 12/29/2017 12/28/2018 1/3/2020 1/1/2021 12/31/2021 12/30/2022 12/29/2023 12/27/2024 1/2/2026
Net Change in Cash & Equivalents		 0.39 0.60 4.52 85 16 32 47 -113 97 -39 8.99
Net Cash From Operating Activities		 -2.16 1.05 2.85 13 26 21 44 36 15 16 -34
Net Cash From Continuing Operating Activities		 -2.16 1.05 2.85 13 26 21 44 36 15 16 -34
Net Income / (Loss) Continuing Operations		 -6.53 -12 -2.14 4.97 14 5.91 28 40 21 -20 -80
Consolidated Net Income / (Loss)		 -6.53 -12 -2.14 4.97 14 5.91 28 40 21 -20 -80
Depreciation Expense		 2.20 2.66 3.13 2.43 3.67 3.06 3.61 4.48 5.11 6.89 8.32
Amortization Expense		 0.21 0.23 0.22 0.03 0.03 0.04 0.03 0.03 0.01 0.00 0.41
Non-Cash Adjustments To Reconcile Net Income		 6.30 9.74 5.92 8.55 11 11 16 20 27 19 40
Changes in Operating Assets and Liabilities, net		 -4.33 0.54 -4.28 -3.22 -3.06 0.80 -3.06 -28 -38 9.96 -2.37
Net Cash From Investing Activities		 -2.04 -3.21 -1.05 -2.25 -10 -8.40 -14 -156 74 -59 46
Net Cash From Continuing Investing Activities		 -2.04 -3.21 -1.05 -2.25 -10 -8.40 -14 -156 74 -59 46
Purchase of Property, Plant & Equipment		 -2.05 -3.21 -1.05 -2.25 -10 -8.40 -14 -18 -18 -23 -5.82
Purchase of Investments		 - - - - - 0.00 0.00 -156 -52 -80 -75
Sale and/or Maturity of Investments		 - - - - - 0.00 0.00 17 145 44 128
Net Cash From Financing Activities		 4.58 2.95 2.44 75 0.15 20 18 8.30 7.42 5.72 -4.56
Net Cash From Continuing Financing Activities		 4.58 2.95 2.44 75 0.15 20 18 8.30 7.42 5.72 -4.56
Repayment of Debt		 -0.39 -0.42 -1.30 -2.65 -3.31 -1.08 -1.65 -0.13 -0.16 -0.17 -0.04
Repurchase of Common Equity		 - - - - - - - - 0.00 0.00 -6.46
Other Financing Activities, net		 4.97 3.38 3.74 5.14 3.46 21 19 8.42 7.58 5.89 1.95
Effect of Exchange Rate Changes		 0.02 -0.20 0.28 0.20 0.20 0.37 -0.86 -0.86 0.20 -1.11 1.44

Quarterly Cash Flow Statements for STAAR Surgical

This table details how cash moves in and out of STAAR Surgical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/29/2023 3/29/2024 6/28/2024 9/27/2024 12/27/2024 3/28/2025 6/27/2025 9/26/2025 1/2/2026 4/3/2026 7/3/2026
Net Change in Cash & Equivalents		 56 41 -31 -29 -20 29 -5.98 9.02 -23 -21 17
Net Cash From Operating Activities		 32 22 -10 3.82 0.64 -5.73 -27 2.67 -3.91 -22 20
Net Cash From Continuing Operating Activities		 32 22 -10 3.82 0.64 -5.73 -27 2.67 -3.91 -22 20
Net Income / (Loss) Continuing Operations		 7.76 -3.34 7.38 9.98 -34 -54 -17 8.88 -18 5.21 8.06
Consolidated Net Income / (Loss)		 7.76 -3.34 7.38 9.98 -34 -54 -17 8.88 -18 5.21 8.06
Depreciation Expense		 1.37 1.24 1.52 1.76 2.38 2.34 1.98 2.00 2.01 2.11 2.39
Amortization Expense		 -0.16 0.00 - - - 0.05 - - 0.41 0.10 0.95
Non-Cash Adjustments To Reconcile Net Income		 -0.29 1.51 8.63 5.24 0.14 19 6.14 9.17 6.13 7.42 14
Changes in Operating Assets and Liabilities, net		 23 22 -28 -13 32 27 -19 -17 5.85 -37 -6.06
Net Cash From Investing Activities		 22 16 -21 -35 -19 35 25 5.28 -19 2.15 -1.37
Net Cash From Continuing Investing Activities		 22 16 -21 -35 -19 35 25 5.28 -19 2.15 -1.37
Purchase of Property, Plant & Equipment		 -3.09 -5.20 -6.24 -6.23 -5.73 -1.47 -1.79 -0.88 -1.68 -0.44 -0.49
Purchase of Investments		 0.00 0.00 -20 -41 -19 -15 - -12 -49 -4.52 -28
Sale and/or Maturity of Investments		 25 21 5.82 12 5.28 52 27 18 31 7.11 27
Net Cash From Financing Activities		 0.37 4.06 0.16 1.62 -0.11 -0.95 -4.54 0.98 -0.05 -1.69 -1.50
Net Cash From Continuing Financing Activities		 0.37 4.06 0.16 1.62 -0.11 -0.95 -4.54 0.98 -0.05 -1.69 -1.50
Other Financing Activities, net		 0.41 4.10 0.21 1.66 -0.07 -0.91 -0.06 2.97 -0.05 -1.69 -1.50
Effect of Exchange Rate Changes		 0.87 -0.94 -0.33 1.04 -0.88 0.29 0.69 0.09 0.37 -0.05 -0.11

Annual Balance Sheets for STAAR Surgical

This table presents STAAR Surgical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/1/2016 12/30/2016 12/29/2017 12/28/2018 1/3/2020 1/1/2021 12/31/2021 12/30/2022 12/29/2023 12/27/2024 1/2/2026
Total Assets		 63 65 68 167 208 257 346 419 489 510 452
Total Current Assets		 49 50 54 152 175 216 271 312 365 368 312
Cash & Equivalents		 13 14 19 104 120 152 200 86 183 144 153
Short-Term Investments		 - - - - - - 0.00 125 38 86 34
Accounts Receivable		 16 16 18 26 31 35 44 62 95 78 50
Inventories, net		 16 15 13 17 17 18 17 24 35 43 55
Prepaid Expenses		 3.64 4.35 4.21 5.05 6.56 11 11 13 15 16 18
Plant, Property, & Equipment, net		 10 12 9.78 11 17 24 36 51 67 85 73
Total Noncurrent Assets		 3.79 4.17 4.27 4.32 16 17 38 56 57 57 67
Goodwill		 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79
Intangible Assets		 0.67 0.47 0.27 0.24 0.30 0.27 0.22 0.17 0.00 - 31
Noncurrent Deferred & Refundable Income Taxes		 0.72 1.14 1.24 1.28 4.41 4.94 3.81 8.74 5.19 0.79 3.37
Other Noncurrent Operating Assets		 0.62 0.77 0.97 1.01 7.44 9.37 32 31 38 54 31
Total Liabilities & Shareholders' Equity		 63 65 68 167 208 257 346 419 489 510 452
Total Liabilities		 24 28 25 35 48 60 87 83 103 112 107
Total Current Liabilities		 18 21 19 28 34 41 49 52 65 70 69
Accounts Payable		 6.69 8.31 6.03 6.52 8.05 7.47 8.70 12 14 17 12
Other Current Liabilities		 6.31 7.28 7.34 17 25 32 40 40 51 54 57
Total Noncurrent Liabilities		 6.22 6.51 5.91 7.19 13 19 38 31 38 42 39
Asset Retirement Reserve & Litigation Obligation		 0.16 0.20 0.20 0.21 0.21 0.22 0.20 0.22 0.10 0.04 0.05
Noncurrent Deferred Revenue		 0.09 0.06 0.17 0.19 - - - - - 0.00 0.09
Noncurrent Employee Benefit Liabilities		 3.89 4.00 4.65 5.31 7.84 12 8.76 1.94 5.06 6.74 6.38
Other Noncurrent Operating Liabilities		 - - - 0.00 4.09 6.54 28 27 31 35 32
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 39 38 43 132 160 197 259 336 386 397 344
Total Preferred & Common Equity		 39 38 43 132 160 197 259 336 386 397 344
Total Common Equity		 39 38 43 132 160 197 259 336 386 397 344
Common Stock		 187 198 205 290 305 339 374 405 437 472 505
Retained Earnings		 -147 -159 -161 -156 -142 -136 -111 -69 -47 -68 -148
Treasury Stock		 - - - - - - - - - 0.00 -6.46
Accumulated Other Comprehensive Income / (Loss)		 -1.58 -1.05 -1.15 -1.32 -3.05 -5.55 -4.05 0.16 -4.11 -7.03 -6.51

Quarterly Balance Sheets for STAAR Surgical

This table presents STAAR Surgical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2022 6/30/2023 9/29/2023 3/29/2024 6/28/2024 9/27/2024 3/28/2025 6/27/2025 9/26/2025 4/3/2026 7/3/2026
Total Assets		 395 441 472 493 513 538 457 438 456 451 475
Total Current Assets		 297 328 347 366 384 397 326 293 321 312 342
Cash & Equivalents		 129 95 127 224 193 164 173 167 176 132 149
Short-Term Investments		 82 97 61 21 42 72 50 23 17 32 33
Accounts Receivable		 55 94 112 65 94 105 40 34 60 81 98
Inventories, net		 20 25 31 39 39 40 48 53 53 50 47
Prepaid Expenses		 10 16 16 17 16 16 16 15 15 18 16
Plant, Property, & Equipment, net		 48 56 63 72 78 82 75 74 73 72 70
Total Noncurrent Assets		 50 57 62 54 51 59 56 71 63 67 63
Goodwill		 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79 1.79
Intangible Assets		 0.17 0.00 0.00 - - - - - - 34 31
Noncurrent Deferred & Refundable Income Taxes		 3.71 4.67 8.56 5.13 5.08 5.32 4.00 12 1.98 1.09 1.09
Other Noncurrent Operating Assets		 30 32 37 40 44 52 50 57 59 30 29
Total Liabilities & Shareholders' Equity		 395 441 472 493 513 538 457 438 456 451 475
Total Liabilities		 75 87 93 100 104 109 107 101 103 99 110
Total Current Liabilities		 45 54 57 63 66 66 68 59 62 61 73
Accounts Payable		 7.57 11 8.79 17 19 15 11 12 9.18 8.70 13
Other Current Liabilities		 38 43 48 46 47 52 57 47 52 52 60
Total Noncurrent Liabilities		 29 33 36 37 37 43 39 42 41 38 36
Asset Retirement Reserve & Litigation Obligation		 0.16 0.10 0.10 0.10 0.11 0.13 0.04 0.05 0.04 0.04 0.04
Noncurrent Deferred Revenue		 - - - - - - - - 0.09 0.09 0.09
Noncurrent Employee Benefit Liabilities		 1.23 3.05 3.03 4.78 4.81 6.56 5.88 6.52 7.01 6.44 6.52
Other Noncurrent Operating Liabilities		 26 28 32 31 31 35 33 35 34 31 30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 320 354 379 393 409 428 350 337 354 352 365
Total Preferred & Common Equity		 320 354 379 393 409 428 350 337 354 352 365
Total Common Equity		 320 354 379 393 409 428 350 337 354 352 365
Common Stock		 399 420 437 448 458 467 477 485 496 508 514
Retained Earnings		 -78 -64 -55 -51 -43 -33 -122 -139 -130 -143 -135
Treasury Stock		 - - - - - - - -4.48 -6.46 -6.46 -6.46
Accumulated Other Comprehensive Income / (Loss)		 -0.31 -2.52 -2.89 -4.71 -5.46 -5.60 -5.60 -5.65 -6.53 -6.78 -6.97

Annual Metrics And Ratios for STAAR Surgical

This table displays calculated financial ratios and metrics derived from STAAR Surgical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/1/2016 12/30/2016 12/29/2017 12/28/2018 1/3/2020 1/1/2021 12/31/2021 12/30/2022 12/29/2023 12/27/2024 1/2/2026
DEI Shares Outstanding		 - - - - - - - - - - 49,741,953.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 49,741,953.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.62
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -3.74 -8.86 -2.54 4.94 13 4.84 29 38 18 -8.83 -64
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 11.34% 4.61% -2.22% -18.65%
Earnings before Interest and Taxes (EBIT)		 -6.27 -13 -2.77 5.84 11 7.59 30 42 27 -15 -87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.87 -10 0.59 8.31 15 11 34 47 32 -8.58 -78
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.80 -9.42 -2.48 2.81 3.46 0.76 16 -13 -25 -22 -54
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 30 31 31 33 42 46 59 111 154 167 157
Increase / (Decrease) in Invested Capital		 1.07 0.56 -0.06 2.13 9.32 4.08 13 52 43 13 -10
Book Value per Share		 $0.97 $0.93 $1.04 $3.00 $3.58 $4.28 $5.43 $6.97 $7.91 $8.06 $6.92
Tangible Book Value per Share		 $0.91 $0.88 $0.99 $2.95 $3.54 $4.23 $5.39 $6.93 $7.87 $8.03 $6.88
Total Capital		 44 45 49 137 162 199 259 336 386 397 344
Total Debt		 4.73 6.82 6.25 4.24 2.19 1.42 0.38 0.21 0.04 0.00 0.00
Total Long-Term Debt		 0.20 1.34 0.53 0.46 0.37 0.04 0.38 0.21 0.04 0.00 0.00
Net Debt		 -8.68 -7.18 -12 -100 -118 -151 -199 -225 -232 -230 -188
Capital Expenditures (CapEx)		 2.04 3.21 1.05 2.25 10 8.40 14 18 18 23 5.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 22 20 22 24 22 24 23 48 80 67 56
Debt-free Net Working Capital (DFNWC)		 36 34 41 128 142 177 223 260 300 298 243
Net Working Capital (NWC)		 31 28 35 124 140 175 223 260 300 298 243
Net Nonoperating Expense (NNE)		 2.80 3.27 -0.40 -0.03 -1.27 -1.07 1.79 -1.52 -3.55 11 16
Net Nonoperating Obligations (NNO)		 -8.68 -7.18 -12 -100 -118 -151 -199 -225 -232 -230 -188
Total Depreciation and Amortization (D&A)		 2.40 2.89 3.35 2.46 3.70 3.10 3.64 4.51 5.12 6.89 8.73
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.30) ($0.05) $0.12 $0.32 $0.13 $0.52 $0.81 $0.44 ($0.41) ($1.62)
Adjusted Weighted Average Basic Shares Outstanding		 39.26M 40.75M 41.42M 42.59M 44.49M 45.61M 47.21M 47.99M 48.52M 49.13M 49.57M
Adjusted Diluted Earnings per Share		 ($0.17) ($0.30) ($0.05) $0.11 $0.30 $0.12 $0.50 $0.78 $0.43 ($0.41) ($1.62)
Adjusted Weighted Average Diluted Shares Outstanding		 39.26M 40.75M 41.42M 45.26M 46.90M 47.95M 49.46M 49.38M 49.43M 49.13M 49.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.30) ($0.05) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.16M 40.33M 41.00M 44.21M 44.96M 46.56M 47.75M 48.24M 48.87M 49.33M 49.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.74 -8.86 -2.54 4.94 8.30 4.84 29 38 18 -8.83 -44
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for STAAR Surgical

This table displays calculated financial ratios and metrics derived from STAAR Surgical's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/29/2023 3/29/2024 6/28/2024 9/27/2024 12/27/2024 3/28/2025 6/27/2025 9/26/2025 1/2/2026 4/3/2026 7/3/2026
DEI Shares Outstanding		 - - - - - - - - 49,741,953.00 49,512,749.00 49,512,749.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 49,741,953.00 49,512,749.00 49,512,749.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.37 0.11 0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 19.09% 5.21% 7.26% 10.31% -35.82% -44.94% -55.23% 6.93% - 119.59% 111.04%
EBITDA Growth		 137.75% -174.96% 27.77% 113.58% -322.70% -1,677.32% -342.53% 48.05% - 117.81% 153.36%
EBIT Growth		 187.49% -246.63% 32.68% 135.89% -364.84% -1,214.78% -406.12% 53.17% - 113.09% 136.97%
NOPAT Growth		 438.69% -199.30% 38.39% -4.13% -432.61% -2,416.48% -346.89% 102.87% - 112.58% 135.20%
Net Income Growth		 14.68% -223.21% 21.69% 107.18% -541.31% -1,523.57% -327.84% -10.98% - 109.60% 147.93%
EPS Growth		 14.29% -240.00% 25.00% 100.00% -531.25% -1,471.43% -326.67% -10.00% - 109.09% 147.06%
Operating Cash Flow Growth		 976.40% 525.60% -65.13% 163.87% -97.99% -126.45% -161.68% -30.11% - -278.36% 172.26%
Free Cash Flow Firm Growth		 26.84% 103.41% -259.94% 85.78% 11.11% -1,424.33% 103.62% 464.49% - -110.41% -599.49%
Invested Capital Growth		 38.62% -2.50% 0.00% 8.60% 8.64% -9.57% -15.52% -16.16% - 48.16% 25.37%
Revenue Q/Q Growth		 -5.02% 1.42% 27.99% -10.52% -44.75% -12.99% 4.06% 113.75% - 61.80% 0.01%
EBITDA Q/Q Growth		 109.52% -122.72% 446.53% 29.47% -318.46% -81.33% 52.71% 179.03% - 149.32% 40.98%
EBIT Q/Q Growth		 141.67% -135.28% 309.79% 31.87% -371.33% -75.16% 51.15% 165.98% - 133.65% 37.94%
NOPAT Q/Q Growth		 30.68% -127.18% 632.08% -49.28% -553.37% -105.66% 47.80% 141.68% - 131.62% 46.07%
Net Income Q/Q Growth		 61.01% -143.05% 320.99% 35.25% -442.97% -58.38% 68.99% 152.84% - 128.43% 54.78%
EPS Q/Q Growth		 60.00% -143.75% 314.29% 33.33% -445.00% -59.42% 69.09% 152.94% - 127.78% 60.00%
Operating Cash Flow Q/Q Growth		 635.05% -32.18% -148.03% 136.65% -83.18% -993.15% -375.22% 109.79% - -454.29% 190.76%
Free Cash Flow Firm Q/Q Growth		 51.91% 105.47% -8,286.30% 93.39% -200.59% 18.58% 122.36% 566.08% - -870.23% 46.92%
Invested Capital Q/Q Growth		 -13.21% -8.39% 23.43% 10.67% -13.18% -23.75% 15.31% 9.84% - 20.32% -2.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 79.62% 78.90% 79.20% 77.31% 64.65% 65.76% 74.01% 82.21% - 73.63% 74.55%
EBITDA Margin		 17.37% -3.89% 10.54% 15.25% -60.29% -125.65% -57.10% 21.11% - 10.18% 14.35%
Operating Margin		 13.64% -2.95% 12.02% 6.41% -57.02% -134.78% -67.61% 19.52% - 8.53% 10.80%
EBIT Margin		 15.79% -5.49% 9.00% 13.27% -65.14% -131.14% -61.55% 19.00% - 7.82% 10.78%
Profit (Net Income) Margin		 10.17% -4.32% 7.45% 11.27% -69.92% -127.29% -37.93% 9.38% - 5.57% 8.62%
Tax Burden Percent		 56.45% 151.02% 71.41% 75.84% 112.84% 99.50% 64.87% 47.28% - 63.35% 73.10%
Interest Burden Percent		 114.11% 52.05% 115.96% 111.97% 95.13% 97.55% 94.99% 104.39% - 112.41% 109.31%
Effective Tax Rate		 43.55% 0.00% 28.59% 24.16% 0.00% 0.00% 0.00% 52.72% - 36.65% 26.90%
Return on Invested Capital (ROIC)		 18.79% -4.73% 32.91% 8.99% -78.20% -196.61% -66.32% 12.05% - 9.94% 16.22%
ROIC Less NNEP Spread (ROIC-NNEP)		 17.96% -3.97% 33.86% 6.40% -71.86% -190.70% -68.28% 11.98% - 9.86% 15.85%
Return on Net Nonoperating Assets (RNNOA)		 -11.39% 2.46% -19.49% -3.47% 42.46% 121.92% 38.95% -6.57% - -5.43% -8.39%
Return on Equity (ROE)		 7.40% -2.27% 13.42% 5.52% -35.74% -74.69% -27.37% 5.48% - 4.51% 7.83%
Cash Return on Invested Capital (CROIC)		 -18.90% 11.77% -182.40% 0.41% -13.80% -25.34% -31.07% -20.78% - -50.49% -20.68%
Operating Return on Assets (OROA)		 11.22% -3.84% 5.85% 8.97% -40.97% -77.07% -29.07% 8.82% - 5.00% 8.02%
Return on Assets (ROA)		 7.23% -3.02% 4.84% 7.62% -43.98% -74.81% -17.91% 4.35% - 3.56% 6.41%
Return on Common Equity (ROCE)		 7.40% -2.27% 13.42% 5.52% -35.74% -74.69% -27.37% 5.48% - 4.51% 7.83%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 3.89% 4.06% 5.09% 0.00% -20.31% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 5.87 -1.60 8.50 4.31 -20 -40 -21 8.74 -16 5.05 7.38
NOPAT Margin		 7.70% -2.06% 8.58% 4.86% -39.91% -94.35% -47.33% 9.23% - 5.40% 7.89%
Net Nonoperating Expense Percent (NNEP)		 0.82% -0.76% -0.95% 2.59% -6.35% -5.91% 1.96% 0.07% - 0.08% 0.36%
Return On Investment Capital (ROIC_SIMPLE)		 1.52% - - - -4.92% -11.48% -6.23% 2.47% -4.64% 1.43% 2.02%
Cost of Revenue to Revenue		 20.38% 21.10% 20.80% 22.69% 35.35% 34.24% 26.00% 17.79% - 26.37% 25.45%
SG&A Expenses to Revenue		 22.10% 30.03% 23.88% 24.48% 43.60% 57.43% 47.31% 21.92% - 18.20% 24.31%
R&D to Revenue		 14.25% 17.30% 14.20% 16.36% 24.60% 32.08% 23.16% 9.72% - 10.61% 10.63%
Operating Expenses to Revenue		 65.97% 81.85% 67.18% 70.89% 121.67% 200.54% 141.61% 62.69% - 65.10% 63.75%
Earnings before Interest and Taxes (EBIT)		 12 -4.25 8.91 12 -32 -56 -27 18 -22 7.31 10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 13 -3.01 10 14 -30 -54 -25 20 -19 9.52 13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.95 4.76 5.72 4.28 3.00 2.51 2.49 3.75 - 2.84 3.77
Price to Tangible Book Value (P/TBV)		 3.97 4.78 5.74 4.30 3.02 2.52 2.50 3.77 - 3.16 4.14
Price to Revenue (P/Rev)		 4.73 5.73 7.03 5.37 3.80 3.14 3.73 5.76 - 3.45 4.05
Price to Earnings (P/E)		 71.37 122.16 140.80 84.10 0.00 0.00 0.00 0.00 - 0.00 358.42
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 1.40% 0.82% 0.71% 1.19% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.28%
Enterprise Value to Invested Capital (EV/IC)		 8.41 11.49 12.12 8.30 5.77 5.15 4.42 7.05 - 4.44 6.49
Enterprise Value to Revenue (EV/Rev)		 4.00 4.96 6.32 4.68 3.07 2.35 2.89 4.92 - 2.88 3.52
Enterprise Value to EBITDA (EV/EBITDA)		 40.66 65.37 77.91 46.67 0.00 0.00 0.00 0.00 - 0.00 50.96
Enterprise Value to EBIT (EV/EBIT)		 48.48 82.94 97.01 56.06 0.00 0.00 0.00 0.00 - 0.00 87.37
Enterprise Value to NOPAT (EV/NOPAT)		 72.54 122.89 137.65 99.82 0.00 0.00 0.00 0.00 - 0.00 393.80
Enterprise Value to Operating Cash Flow (EV/OCF)		 88.48 39.08 56.46 33.91 61.21 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 96.41 0.00 2,105.46 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -0.63 -0.62 -0.58 -0.54 -0.59 -0.64 -0.57 -0.55 - -0.55 -0.53
Leverage Ratio		 1.26 1.25 1.25 1.25 1.27 1.28 1.27 1.27 - 1.29 1.30
Compound Leverage Factor		 1.43 0.65 1.45 1.40 1.21 1.25 1.21 1.33 - 1.45 1.42
Debt to Total Capital		 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 99.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 -7.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 -13.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 10.24 12.47 14.87 11.40 7.31 5.41 5.47 8.69 - 7.00 8.59
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.62 5.84 5.80 5.99 5.23 4.78 4.94 5.21 - 5.12 4.66
Quick Ratio		 4.85 4.94 4.97 5.13 4.39 3.84 3.79 4.10 - 4.02 3.81
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -37 2.02 -165 -11 -33 -27 5.97 40 -5.79 -56 -30
Operating Cash Flow to CapEx		 1,035.27% 416.76% -166.98% 61.24% 11.21% -390.60% -1,520.59% 302.04% - -4,897.29% 3,985.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.71 0.70 0.65 0.68 0.63 0.59 0.47 0.46 - 0.64 0.74
Accounts Receivable Turnover		 4.10 4.10 3.55 3.15 3.64 5.34 3.50 2.80 - 4.79 5.11
Inventory Turnover		 2.35 2.19 1.76 2.03 1.90 1.67 1.37 1.29 - 1.37 1.59
Fixed Asset Turnover		 5.48 5.09 4.30 4.72 4.14 3.79 2.95 2.99 - 3.96 4.71
Accounts Payable Turnover		 5.55 5.01 3.63 6.18 4.91 5.18 4.04 5.05 - 6.66 6.15
Days Sales Outstanding (DSO)		 88.95 88.97 102.83 115.99 100.35 68.36 104.27 130.28 - 76.12 71.43
Days Inventory Outstanding (DIO)		 155.10 166.74 207.40 179.63 192.61 218.06 265.49 283.64 - 266.34 229.75
Days Payable Outstanding (DPO)		 65.75 72.88 100.63 59.05 74.31 70.47 90.24 72.30 - 54.83 59.36
Cash Conversion Cycle (CCC)		 178.31 182.83 209.60 236.57 218.65 215.95 279.52 341.63 - 287.63 241.83
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 154 141 174 192 167 127 147 161 157 188 184
Invested Capital Turnover		 2.44 2.29 3.83 1.85 1.96 2.08 1.40 1.31 - 1.84 2.05
Increase / (Decrease) in Invested Capital		 43 -3.61 174 15 13 -13 -27 -31 -10 61 37
Enterprise Value (EV)		 1,291 1,617 2,104 1,595 962 655 648 1,135 - 837 1,194
Market Capitalization		 1,524 1,869 2,339 1,831 1,193 877 838 1,328 - 1,001 1,376
Book Value per Share		 $7.91 $8.03 $8.33 $8.70 $8.06 $7.10 $6.80 $7.14 $6.92 $7.12 $7.26
Tangible Book Value per Share		 $7.87 $7.99 $8.29 $8.67 $8.03 $7.06 $6.76 $7.10 $6.88 $6.39 $6.60
Total Capital		 386 393 409 428 397 350 337 354 344 352 365
Total Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -232 -252 -235 -236 -230 -223 -190 -193 -188 -164 -181
Capital Expenditures (CapEx)		 3.09 5.20 6.24 6.23 5.73 1.47 1.79 0.88 1.68 0.44 0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 80 58 82 95 67 35 44 67 56 88 87
Debt-free Net Working Capital (DFNWC)		 300 303 318 331 298 258 234 260 243 251 269
Net Working Capital (NWC)		 300 303 318 331 298 258 234 260 243 251 269
Net Nonoperating Expense (NNE)		 -1.88 1.74 1.12 -5.67 15 14 -4.16 -0.14 2.32 -0.15 -0.67
Net Nonoperating Obligations (NNO)		 -232 -252 -235 -236 -230 -223 -190 -193 -188 -164 -181
Total Depreciation and Amortization (D&A)		 1.21 1.24 1.52 1.76 2.38 2.34 1.98 2.00 2.42 2.21 3.34
Debt-free, Cash-free Net Working Capital to Revenue		 24.66% 17.75% 24.76% 27.78% 21.39% 12.68% 19.46% 29.02% - 30.14% 25.76%
Debt-free Net Working Capital to Revenue		 93.12% 92.89% 95.41% 96.93% 94.82% 92.48% 104.06% 112.57% - 86.58% 79.20%
Net Working Capital to Revenue		 93.12% 92.89% 95.41% 96.93% 94.82% 92.48% 104.06% 112.57% - 86.58% 79.20%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.15 ($0.07) $0.15 $0.20 ($0.69) ($1.10) ($0.34) $0.18 ($0.36) $0.10 $0.16
Adjusted Weighted Average Basic Shares Outstanding		 48.52M 48.91M 49.13M 49.20M 49.13M 49.34M 49.52M 49.63M 49.57M 49.91M 50.32M
Adjusted Diluted Earnings per Share		 $0.16 ($0.07) $0.15 $0.20 ($0.69) ($1.10) ($0.34) $0.18 ($0.36) $0.10 $0.16
Adjusted Weighted Average Diluted Shares Outstanding		 49.43M 48.91M 49.81M 49.73M 49.13M 49.34M 49.52M 50.55M 49.57M 50.90M 51.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.87M 49.13M 49.19M 49.28M 49.33M 49.53M 49.55M 49.74M 49.51M 0.00 50.14M
Normalized Net Operating Profit after Tax (NOPAT)		 5.87 -1.60 8.50 4.31 -20 -24 -17 13 -16 6.75 7.38
Normalized NOPAT Margin		 7.70% -2.06% 8.58% 4.86% -39.91% -57.09% -39.04% 13.68% - 7.22% 7.89%
Pre Tax Income Margin		 18.01% -2.86% 10.44% 14.85% -61.97% -127.93% -58.47% 19.83% - 8.79% 11.79%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 51.63%

Financials Breakdown Chart

Key Financial Trends

STAAR Surgical’s latest quarter shows a sharp rebound in profitability, but cash flow remains under pressure. In Q1 2026, revenue rose to $93.5 million, up from $57.8 million in Q4 2025 and $42.6 million in Q1 2025. The company also swung back to profitability with $5.2 million in net income, compared with a loss of $18.3 million in the prior quarter.

That said, the cash flow picture is still mixed. Operating cash flow was negative $21.7 million in Q1 2026, and the company ended the quarter with $131.9 million in cash and equivalents plus $32.0 million in short-term investments. That gives STAAR a solid liquidity cushion, but the quarter also showed a meaningful outflow from working capital.

Over the last four years, the trend has been choppy: revenue has fluctuated, losses have widened during some periods, and the company has taken restructuring charges while marketing costs stayed elevated. At the same time, STAAR has generally maintained a strong balance sheet with more cash than debt and substantial equity.

  • Revenue rebounded strongly in Q1 2026 to $93.5 million, up 62% from Q4 2025 and 28% from Q1 2025.
  • Returned to profitability with net income of $5.2 million in Q1 2026 after a $18.3 million loss in Q4 2025.
  • Gross profit improved to $68.9 million, reflecting much better top-line leverage.
  • Cash and investments remain substantial at about $163.9 million combined, supporting near-term flexibility.
  • Long-term debt appears minimal, which reduces financial risk.
  • Operating expenses remain high, especially marketing, which was $24.5 million in Q1 2026.
  • Accounts receivable and inventories are meaningful, so investors should watch working-capital efficiency.
  • R&D spending is still modest relative to sales at about $9.9 million in Q1 2026.
  • Operating cash flow was negative by $21.7 million in Q1 2026, showing earnings have not yet translated into cash.
  • Working-capital changes were a drag, with a $36.5 million negative impact in operating assets and liabilities.

The longer-term pattern is important for investors. In 2024 and early 2025, STAAR repeatedly posted either losses or only small profits, while marketing and restructuring expenses weighed heavily on operating results. The latest quarter suggests the business can still generate strong sales and earnings when conditions improve, but consistency remains the key question.

Bottom line: STAAR Surgical looks healthier on the income statement in the latest quarter, but the company still needs to prove that improving revenue can turn into durable operating cash flow. Investors may view the balance sheet as a source of support, but the path to sustained earnings power is still not fully smooth.

08/14/26 07:37 PM ETAI Generated. May Contain Errors.

STAAR Surgical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, STAAR Surgical's financial year ends in January. Their financial year 2026 ended on January 2, 2026.

STAAR Surgical's net income appears to be on an upward trend, with a most recent value of -$80.45 million in 2025, rising from -$6.53 million in 2015. The previous period was -$20.21 million in 2024. Check out STAAR Surgical's forecast to explore projected trends and price targets.

STAAR Surgical's total operating income in 2025 was -$91.71 million, based on the following breakdown:
  • Total Gross Profit: $182.42 million
  • Total Operating Expenses: $274.13 million

Over the last 10 years, STAAR Surgical's total revenue changed from $77.12 million in 2015 to $239.44 million in 2025, a change of 210.5%.

STAAR Surgical's total liabilities were at $107.49 million at the end of 2025, a 4.2% decrease from 2024, and a 345.9% increase since 2015.

In the past 10 years, STAAR Surgical's cash and equivalents has ranged from $13.40 million in 2015 to $199.71 million in 2021, and is currently $153.15 million as of their latest financial filing in 2025.

Over the last 10 years, STAAR Surgical's book value per share changed from 0.97 in 2015 to 6.92 in 2025, a change of 610.5%.


Related Companies

Financial statements for NASDAQ:STAA last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Huge AI Announcement Coming on September 3
A $51 billion backlog, a SpaceX partnership, and a presidential endorsement are fueling renewed attention on t...
InvestorPlace | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel